MIR433 (MicroRNA 433)

The current findings identified miR-4330 restoration as a tool for overcoming acquired drug resistance and reducing cancer activity, which might be used to improve therapeutic strategies and treatment regimens for breast cancer patients. miR-4330 may be useful as a diagnostic and prognostic marker for drug-resistant breast cancer.

The PNPLA3 p.I148M genotype was not associated with altered levels of microRNAs. Serum microRNAs, in particular miR-4651, may serve as additional biomarkers in patients with steatotic liver disease.

The study highlights differential regulation of circulating and tissue miRNAs in Indian OC patients, emphasizing the selective retention of oncogenic miRNAs in tumors and release of tumor suppressive miRNAs into circulation. These findings support the utility of miRNAs as diagnostic and prognostic biomarkers in OC.

Hsa_circ_0005325 is highly expressed in SCC25 and CAL-27 cells. Downregulation of hsa_circ_0005325 can inhibit the proliferation and invasion of SCC25 and CAL-27 cells and promote their apoptosis.

The findings of this study suggest that miR-214 and miR-433 can downregulate PTEN whereas miR-100 and miR-152 may have a tumour suppressive role like PTEN. Thus, the signature miR network has the potential to become a diagnostic and prognostic biomarker.

This study reveals that circPRDM5 promotes neuronal damage in PD by sponging miR-433-3p and upregulating HDAC6, contributing to apoptosis and autophagy. Knockdown of circPRDM5 reduces PD-like symptoms in both cellular and animal models, providing a potential therapeutic target for PD. Targeting the circPRDM5/miR-433-3p/HDAC6 axis may offer new opportunities for disease-modifying treatments in PD.

Furthermore, overexpression of miR-433 was found to inhibit the invasion ability of glioblastoma cells by targeting TRPM8. These data demonstrate that miR-433 can target TRPM8 to inhibit glioblastoma cell invasion.

Our study represents the first attempt to investigate the expression of GATA3 and its targeting miRNAs simultaneously in breast cancer. Our findings suggest that dysregulation of these genes may contribute to breast cancer development and progression.

In addition, genes related to MS4A6A contribute to immune and inflammatory-related biological processes. Our findings provide novel insights to understand the ceRNA regulation in GBM and identify novel prognostic biomarkers or therapeutic targets.

The hsa-miR-502-5p targets SET D8, T RAF2 and others and suggests additional genomic/epigenomic molecular targets for promising therapeutic interventions in EC. Predicted miRNAs target a number of mRNAs having varied functional impacts and offer an in-depth mechanistic insights for expatiating the biological and regulatory role in EC.Communicated by Ramaswamy H. Sarma.

MALAT1 is highly expressed in endotoxemia. MALAT1 promotes RPTOR expression by competitively absorbing miR-433-3p, inhibits LPS-activated HUVEC cell autophagy, promotes cell death, enhances LPS-induced inflammatory activation of vascular endothelial cells, and ultimately promotes the progression of endotoxemia.

The combination of evogliptin and TMZ had a moderate effect on the treatment of GBM in vitro and in vivo. miR-4440 and miR-6780b-5p could be associated with inhibiting the proliferation of GBM cells by targeting DPP4.